|Title:||Inhibitory effects of chitooligosaccharides on tumor growth and metastasis||Authors:||Shen K.-T.
|Keywords:||Cell cycle; Chitooligosaccharides; SCID mice; Tumor growth; Tumor metastasis||Issue Date:||2009||Journal Volume:||47||Journal Issue:||8||Start page/Pages:||1864-1871||Source:||Food and Chemical Toxicology||Abstract:||
Chitooligosaccharides (COS) are hydrolyzed products of chitosan and have been proven to exhibit various biological functions. The objectives of this study were to evaluate the anti-tumor growth, anti-metastatic potency and related pathways of COS extracted from fungi. In in vitro studies, we found that COS significantly inhibited human hepatocellular carcinoma (HepG2) cell proliferation, reduced the percentage of S-phase and decreased DNA synthesis rate in COS-treated HepG2 cells. Expressions of cell cycle-related genes were analyzed and the results indicated that p21 was up-regulated, while PCNA, cyclin A and cdk-2 were down-regulated. Moreover, we also found that the activity of metastatic related protein (MMP-9) could be inhibited by COS in Lewis lung carcinoma (LLC) cells. In in vivo studies, we found that COS inhibited the tumor growth of HepG2 xenografts in severe combined immune deficient (SCID) mice. In a LLC-bearing mouse tumor growth and lung metastasis model, COS inhibited tumor growth and the number of lung colonies in LLC-bearing mice as well as the lung metastasis, and it prolonged the survival time of the LLC-mice. These results suggest a potential anti-tumor growth and anti-metastatic potency of COS in cancer chemoprevention. ? 2009 Elsevier Ltd. All rights reserved.
|Appears in Collections:||臨床牙醫學研究所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.